Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
Author:
Linda Bouhlel,Jérôme Doyen,Emmanuel Chamorey,Michel Poudenx,Marius Ilie,Jocelyn Gal,Joël Guigay,Jonathan Benzaquen,Charles-Hugo Marquette,Jean-Philippe Berthet,Jérôme Mouroux,Renaud Schiappa,Bernard Padovani,Paul Hofman,Josiane Otto
Publication:
Bulletin du Cancer
© 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.